Evidence map›Paper›PMID 37316937›Full record

ArticleCell communication and signaling : CCS2023

The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis.

Shakti Ranjan Satapathy, Souvik Ghatak, Anita Sjölander

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Cell communication and signaling : CCS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Autocrine CysLTOncogene · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shakti Ranjan SatapathyCell and Experimental Pathology, Department of Translational Medicine, Clinical Research Center, Lund University, Skåne University Hospital, Jan Waldenströms Gata 35, 205 02, Malmö, Sweden. shakti_ranjan.satapathy@med.lu.se.
Souvik GhatakCell and Experimental Pathology, Department of Translational Medicine, Clinical Research Center, Lund University, Skåne University Hospital, Jan Waldenströms Gata 35, 205 02, Malmö, Sweden.
Anita SjölanderCell and Experimental Pathology, Department of Translational Medicine, Clinical Research Center, Lund University, Skåne University Hospital, Jan Waldenströms Gata 35, 205 02, Malmö, Sweden. anita.sjolander@med.lu.se.
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal cancer (CRC), only a subset of patients benefit from PD-1/PD-L1 treatment. Previously, we showed that high cysteinyl leukotriene receptor 1 (CysLT

Indexed as

CarcinogensColonic NeoplasmsAcetatesAnimalsB7-H1 Antigenbeta CateninCyclopropanesMiceProgrammed Cell Death 1 ReceptorQuinolinesReceptors, LeukotrieneSulfidesWnt Signaling PathwayAcetatesB7-H1 Antigenbeta CateninCarcinogensCD274 protein, humanCyclopropanesleukotriene D4 receptormontelukastProgrammed Cell Death 1 ReceptorQuinolinesReceptors, LeukotrieneSulfidesColon cancerCysteinyl leukotriene receptorPD-L1Wnt/β-catenin

Identifiers

PMID37316937
PMCPMC10265834
OpenAlexW4380682329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.